May 25 (Reuters) - Biosyent Inc:
* Biosyent signs exclusive distribution agreement for two
new cardiovascular products
* Intends to submit dossier seeking marketing approval of
products to Health Canada in 2016
* Forecasts that the new products will add approximately CAD
$20 million to overall revenue of company when they reach "peak
sales"
Source text for Eikon:
Further company coverage: RX.V